Monthly Archives: April 2012

Cracking the Adherence Nut: Drug Delivery

By Guest Blogger | Published: April 18, 2012
Chris Evans, West Pharmaceutical Services, and Ed Geiselhart, Insight Product Development, consider the importance of drug delivery systems in facilitating patient adherence. No two patients are alike, but drug-makers may not consider how different a single patient’s perspective can be when viewed over time. A patient’s progress through disease management is a journey, and perceptions change [...]
Posted in Guest Blog, Patient Communication, Strategy, healthcare, patient compliance, patient education | Tagged , , , | Leave a comment

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

By Guest Blogger | Published: April 18, 2012
Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will work. [...]
Posted in Global, Guest Blog, Strategy, leadership | Tagged , , , , , | Leave a comment

Supreme Court to Consider Sales Rep Overtime

By Reid Paul | Published: April 12, 2012
Posted in Legal, Marketing, People, Podcasts, Sales, Strategy, compliance | Leave a comment

Trust Issues: Dealing with Academia

By Ben Comer | Published: April 11, 2012
Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry. On exiting a theater, writers are often astounded and dismayed by the film resulting from a screenplay they’ve sold to a producer. Punch-up writers have added corny jokes, directors have [...]
Posted in Biotech, Deals, IP, R&D, Strategy, Technology, leadership | Tagged , , , , | 1 Comment

Supreme Court Considers the Affordable Care Act

By Reid Paul | Published: April 9, 2012
Posted in Corporate Responsibility, Legal, Regulatory, Strategy, healthcare | Tagged , , , , , , , , | Leave a comment